Tecfidera® 240mg magensaftresistente hartkapseln (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-003481-25-DE (EUCTR) | 13/05/2015 | 17/02/2015 | Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple Sclerosis | A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis - DIMAT-MS | relapsing remitting multiple sclerosis MedDRA version: 19.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera® 120mg magensaftresistente Hartkapseln INN or Proposed INN: Dimethyl fumarate Other descriptive name: DIMETHYL FUMARATE Trade Name: Tecfidera® 240mg magensaftresistente Hartkapseln INN or Proposed INN: Dimethyl fumarate Other descriptive name: DIMETHYL FUMARATE | Universitätsklinikum Münster | NULL | Not Recruiting | Female: yes Male: yes | 67 | Phase 4 | Germany |